The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results

Atezolizumab combined to carboplatin and etoposide prolonged survival in the IMpower133 trial of untreated extensive-stage small-cell lung cancer (ES-SCLC). Aim of this analysis is to provide end-of-study results from the phase IIIb MAURIS study on the efficacy and safety of atezolizumab plus chemotherapy in the same disease setting, in a patient population with broader inclusion criteria. MAURIS is a multicentric, open-label, single-arm study conducted between 2019 and 2023 in 25 Italian study centres. A total of 155 patients with untreated ES-SCLC were enrolled. Treatment was based on atezolizumab 1200 mg + carboplatin + etoposide every 21 days, for 4 to 6 cycles, during the induction phase, and atezolizumab every 3 weeks during the maintenance phase. Safety, overall survival (OS) and progression-free survival (PFS) were among study endpoints. The median OS at end of study was 10.6 months, with OS rates of 45.5% at 1 year, 31.0% at 1.5 years, 17.1% at 2 years and 14.5% at 3 years. The median PFS was 5.5 months. Serious adverse events (AEs) occurred in 38.3% of patients, treatment-related serious AEs in 21.4%, and immuno-mediated treatment-emergent AEs in 26.6% of patients. Immune-mediated grade 3 to 4 AEs were inversely related with mortality (hazard ratio, HR = 0.36; 95% confidence interval, CI: 0.13-0.97) in a multivariate analysis. This study showed consistent findings with the IMpower133 trial on the safety and efficacy of atezolizumab plus chemotherapy in first-line treatment of ES-SCLC. Long-term survival of a subgroup of patients was also confirmed.